DETAILS, FICTION AND CLINICAL TRIAL RECRUITMENT FOR ABBV-744 STUDY

In Phase A, individuals will receive different doses and schedules of oral ABBV-744 pill to discover Protected dosing regimen. Supplemental participants will be enrolled at the determined monotherapy dosign regimen. In Phase B, individuals will acquire oral ruxolitinib and ABBV-744 might be presented as "insert-on" therapy. In Segment C, contributo